Rachael Purri1, Laura Brennan2, Jacqueline Rick1, Sharon X Xie3, Benjamin L Deck4, Lana M Chahine5, Nabila Dahodwala1, Alice Chen-Plotkin1, John E Duda1,6, James F Morley1,6, Rizwan S Akhtar1, John Q Trojanowski7, Andrew Siderowf1, Daniel Weintraub1,6,8. 1. Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA. 2. Department of Neurology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA. 3. Department of Biostatistics, Epidemiology, & Informatics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA. 4. Department of Psychology, Drexel University, Philadelphia, Pennsylvania, USA. 5. Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. 6. Parkinson's Disease Research, Education, and Clinical Center, Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA. 7. Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA. 8. Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Abstract
OBJECTIVE: The objective of this study was to determine the frequency and impact of subjective cognitive complaint (SCC) in Parkinson's disease (PD) patients with normal cognition. METHODS: Patients with PD with expert consensus-determined normal cognition at baseline were asked a single question regarding the presence of SCC. Baseline (N = 153) and longitudinal (up to 4 follow-up visits during a 5-year period; N = 121) between-group differences in patients with PD with (+SCC) and without (-SCC) cognitive complaint were examined, including cognitive test performance and self-rated and informant-rated functional abilities. RESULTS: A total of 81 (53%) participants reported a cognitive complaint. There were no between-group differences in global cognition at baseline. Longitudinally, the +SCC group declined more than the -SCC group on global cognition (Mattis Dementia Rating Scale-2 total score, F1,431 = 5.71, P = 0.02), processing speed (Symbol Digit Modalities Test, F1,425 = 7.52, P = 0.006), and executive function (Trail Making Test Part B, F1,419 = 4.48, P = 0.04), although the results were not significant after correction for multiple testing. In addition, the +SCC group was more likely to progress to a diagnosis of cognitive impairment over time (hazard ratio = 2.61, P = 0.02). The +SCC group also demonstrated significantly lower self-reported and knowledgeable informant-reported cognition-related functional abilities at baseline, and declined more on an assessment of global functional abilities longitudinally. CONCLUSIONS: Patients with PD with normal cognition, but with SCC, report poorer cognition-specific functional abilities, and are more likely to be diagnosed with cognitive impairment and experience global functional ability decline long term. These findings suggest that SCC and worse cognition-related functional abilities may be sensitive indicators of initial cognitive decline in PD.
OBJECTIVE: The objective of this study was to determine the frequency and impact of subjective cognitive complaint (SCC) in Parkinson's disease (PD) patients with normal cognition. METHODS:Patients with PD with expert consensus-determined normal cognition at baseline were asked a single question regarding the presence of SCC. Baseline (N = 153) and longitudinal (up to 4 follow-up visits during a 5-year period; N = 121) between-group differences in patients with PD with (+SCC) and without (-SCC) cognitive complaint were examined, including cognitive test performance and self-rated and informant-rated functional abilities. RESULTS: A total of 81 (53%) participants reported a cognitive complaint. There were no between-group differences in global cognition at baseline. Longitudinally, the +SCC group declined more than the -SCC group on global cognition (Mattis Dementia Rating Scale-2 total score, F1,431 = 5.71, P = 0.02), processing speed (Symbol Digit Modalities Test, F1,425 = 7.52, P = 0.006), and executive function (Trail Making Test Part B, F1,419 = 4.48, P = 0.04), although the results were not significant after correction for multiple testing. In addition, the +SCC group was more likely to progress to a diagnosis of cognitive impairment over time (hazard ratio = 2.61, P = 0.02). The +SCC group also demonstrated significantly lower self-reported and knowledgeable informant-reported cognition-related functional abilities at baseline, and declined more on an assessment of global functional abilities longitudinally. CONCLUSIONS:Patients with PD with normal cognition, but with SCC, report poorer cognition-specific functional abilities, and are more likely to be diagnosed with cognitive impairment and experience global functional ability decline long term. These findings suggest that SCC and worse cognition-related functional abilities may be sensitive indicators of initial cognitive decline in PD.
Authors: Gregory M Pontone; James R Williams; Karen E Anderson; Gary Chase; Susanne A Goldstein; Stephen Grill; Elaina S Hirsch; Susan Lehmann; John T Little; Russell L Margolis; Peter V Rabins; Howard D Weiss; Laura Marsh Journal: Mov Disord Date: 2009-07-15 Impact factor: 10.338
Authors: J Dupouy; F Ory-Magne; C Mekies; V Rousseau; M Puel; K Rerat; J Pariente; C Brefel-Courbon Journal: Acta Neurol Scand Date: 2017-08-22 Impact factor: 3.209
Authors: Kara Pigott; Jacqueline Rick; Sharon X Xie; Howard Hurtig; Alice Chen-Plotkin; John E Duda; James F Morley; Lama M Chahine; Nabila Dahodwala; Rizwan S Akhtar; Andrew Siderowf; John Q Trojanowski; Daniel Weintraub Journal: Neurology Date: 2015-09-11 Impact factor: 9.910
Authors: Dag Aarsland; Lucia Batzu; Glenda M Halliday; Gert J Geurtsen; Clive Ballard; K Ray Chaudhuri; Daniel Weintraub Journal: Nat Rev Dis Primers Date: 2021-07-01 Impact factor: 52.329
Authors: Lauren E Kenney; Adrianna M Ratajska; Francesca V Lopez; Catherine C Price; Melissa J Armstrong; Dawn Bowers Journal: Brain Sci Date: 2021-12-30